DGIdb - SIMVASTATIN Drug Record

SIMVASTATIN chembl:CHEMBL1064 Approved

Alternate Names:

RANZOLONT
ZOCOR
ZOCOR HEART-PRO
SIMVASTATIN HYDROXY ACID
SIMVADOR
SIMVASTATIN
C10AA01
MK-733
MK-0733
SYNVINOLIN
LACERSA
FLOLIPID
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
MODUTROL
LIPOVAS
SINVASCOR
CHOLESTAT
NOR-VASTINA
SIMVASTATIN LACTONE
2,2-DIMETHYLBUTYRIC ACID, 8-ESTER WITH (4R,6R)-6-(2-((1S,2S,6R,8S,8AR)-1,2,6,7,8,8A-HEXAHYDRO-8-HYDROXY-2,6-DIMETHYL-1-NAPHTHYL)ETHYL)TETRAHYDRO-4-HYDROXY-2H-PYRAN-2-ONE
SIMCOR
SIMVASTATINUM
SINVACOR
LIPINORM
ZOCORD
EUCOR
KOLESTEVAN
(+)-SIMVASTATIN
VALEMIA
ZOCOR®
SIMVASTATINE
LIPEX
SIVASTIN
LIPONORM
SIMVASTATINA
RECHOL
DENAN
SIMOVIL
SIV691
VELOSTATIN
SIMVOTIN
PEPSTATIN
LODALES
rxcui:36567
drugbank:00641
chemidplus:79902-63-9
chembl:CHEMBL1064
pubchem.compound:54454

Drug Info:

Drug Indications	antidyslipidaemic agent
Drug Indications	anticholesterolaemic agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antihypertensive agent
Drug Class	anticholesteremic agents
Year of Approval	1991

(4 More Sources)

Publications:

Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther
de Keyser CE et al., 2013, Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study., Pharmacogenomics
Hu M et al., 2013, Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia., Pharmacogenomics
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Huang et al., 2006, Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients., Eur. J. Clin. Invest.
MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
Pappu et al., 2003, Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia., J. Lab. Clin. Med.
Kocarek et al., 2002, Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes., Drug Metab. Dispos.
Stoebner et al., 2003, [Simvastatin-induced lichen planus pemphigoides]., Ann Dermatol Venereol
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Liu et al., 2003, Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection., J Pharm Biomed Anal
Cenedella et al., 2003, Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats., J. Lipid Res.
Carbonell et al., 2005, Binding thermodynamics of statins to HMG-CoA reductase., Biochemistry
Fiegenbaum M et al., 2005, Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes., Pharmacogenomics J
Stogowska-Nikiciuk et al., 2008, [The influence of simvastatin on hsCRP and some paramneters of hemostasis in patients with ischemic heart disease]., Prz. Lek.
Riessen et al., 1999, Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells., Basic Res. Cardiol.
Ruaño G et al., 2007, Physiogenomic association of statin-related myalgia to serotonin receptors., Muscle Nerve
Luzum JA et al., 2015, Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations., J Cardiovasc Pharmacol
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
Kim KA et al., 2007, Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects., J Clin Pharmacol
Fiegenbaum et al., 2005, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment., Clin. Pharmacol. Ther.
Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
Shin MJ et al., 2005, A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients., Clin Chim Acta
Iwuchukwu OF et al., 2014, Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting., Pharmacogenomics
Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
Hubacek JA et al., 2015, Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population., Eur J Intern Med
Hsieh et al., 2008, Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation., Toxicol. Sci.
Vanderlocht et al., 2006, Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls., J. Neuroimmunol.
Chiou et al., 2006, Kinetics and mechanisms of cholesterol esterase inhibition by cardiovascular drugs in vitro., Indian J. Biochem. Biophys.
Gerdes LU et al., 2000, The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study., Circulation
Andersson ML et al., 2012, A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele., Pharmacogenomics
Kendra KL et al., 2015, A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors., Mol Cancer Ther
Hernández-Romero et al., 2008, Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide., J. Neurochem.
Ruiz-Iruela C et al., 2018, KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment., PLoS One
Hopewell JC et al., 2011, No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study., J Am Coll Cardiol
Han et al., 2005, HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo., Circulation
Murphy et al., 2008, Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients., Am. J. Physiol. Lung Cell Mol. Physiol.
Kumano et al., 2000, HMG-CoA reductase inhibitor induces a transient activation of high affinity nerve growth factor receptor, trk, and morphological differentiation with fatal outcome in PC12 cells., Brain Res.
Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
Becker ML et al., 2009, Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males., Pharmacogenomics
Becker ML et al., 2010, Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy., Pharmacoepidemiol Drug Saf
Sun YM et al., 2009, The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease., Eur J Clin Pharmacol
Takahashi-Yasuno A et al., 2003, Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men., Diabetes Res Clin Pract
Anagnostopoulou K et al., 2007, Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects., Expert Opin Pharmacother
Mohrschladt MF et al., 2005, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia., Eur J Hum Genet
Lee et al., 2004, Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection., Circulation
Voora D et al., 2008, Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response., Circ Cardiovasc Genet
Medina MW et al., 2012, RHOA is a modulator of the cholesterol-lowering effects of statin., PLoS Genet
Undas A et al., 2009, Tissue factor +5466A>G polymorphism determines thrombin formation following vascular injury and thrombin-lowering effects of simvastatin in patients with ischemic heart disease., Atherosclerosis
Tirkkonen et al., 2008, Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study., Drug Saf
Cheung et al., 2001, Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin., Biochim. Biophys. Acta
Nagila A et al., 2009, Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status., Pharmacol Rep
Fu R et al., 2008, Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease., Clin Exp Pharmacol Physiol
Himbergen TM et al., 2005, The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia., J Intern Med
Keskitalo JE et al., 2009, Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin., Pharmacogenomics
Becker ML et al., 2013, Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy., Pharmacogenomics J

SIMVASTATIN F3

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19027114

Sources:
PharmGKB
SIMVASTATIN HMGCR

Interaction Score: 1.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HL 007, simvastatin + amlodipine

Novel drug target Established target

Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

PMIDs:
16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
SIMVASTATIN PLTP

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11566255

Sources:
NCI
SIMVASTATIN ICMT

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SIMVASTATIN GATM

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN SCAP

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16158080

Sources:
PharmGKB
SIMVASTATIN LEPR

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18854995 14625131

Sources:
PharmGKB
SIMVASTATIN KIF6

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30304062 21458191

Sources:
PharmGKB
SIMVASTATIN RYR2

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27839692 25753936

Sources:
PharmGKB
SIMVASTATIN PON1

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19904013 18430057 16238680

Sources:
PharmGKB
SIMVASTATIN CYBA

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15936011

Sources:
PharmGKB
SIMVASTATIN RHOA

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23166513

Sources:
PharmGKB
SIMVASTATIN CEL

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16955753

Sources:
NCI
SIMVASTATIN APOA5

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19530961

Sources:
PharmGKB
SIMVASTATIN THBD

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18663903

Sources:
NCI
SIMVASTATIN ABCA1

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20031551

Sources:
PharmGKB
SIMVASTATIN LIPC

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896

Sources:
PharmGKB
SIMVASTATIN TPM3

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10720627

Sources:
NCI
SIMVASTATIN THBS1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10543307

Sources:
NCI
SIMVASTATIN CETP

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17931083 15856070

Sources:
PharmGKB
SIMVASTATIN CCR2

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15781755

Sources:
NCI
SIMVASTATIN LIF

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16797728

Sources:
NCI
SIMVASTATIN HTR3B

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17600820

Sources:
PharmGKB
SIMVASTATIN IL17A

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18203812

Sources:
NCI
SIMVASTATIN APOE

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10736278

Sources:
PharmGKB
SIMVASTATIN UGT1A9

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25493567

Sources:
PharmGKB
SIMVASTATIN SLCO2B1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24598718

Sources:
PharmGKB
SIMVASTATIN CYP3A5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26164721 24598718 23252946 18695978 17289397 17192506 16321621 15284534

Sources:
NCI PharmGKB
SIMVASTATIN HTR7

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17600820

Sources:
PharmGKB
SIMVASTATIN MMP2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16436088

Sources:
NCI
SIMVASTATIN CYP2C8

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25504632

Sources:
PharmGKB
SIMVASTATIN UGT1A3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN PPARA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24598718 23930676 23252946

Sources:
PharmGKB
SIMVASTATIN NR2E3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SIMVASTATIN HLA-DRB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27839692

Sources:
PharmGKB
SIMVASTATIN SLCO1B3

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN ABCG2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24598718 19842935

Sources:
PharmGKB
SIMVASTATIN UGT2B7

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN ABCC2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22186618

Sources:
PharmGKB
SIMVASTATIN BDNF

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18047562

Sources:
NCI
SIMVASTATIN UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15616150 19891551 19802823 16321621

Sources:
NCI PharmGKB
SIMVASTATIN PIK3CG

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15337692

Sources:
NCI
SIMVASTATIN CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22594507 17289397 22931300

Sources:
DTC PharmGKB
SIMVASTATIN NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN TARDBP

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SIMVASTATIN CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
SIMVASTATIN PLK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SIMVASTATIN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18302447 22931300

Sources:
DTC NCI
SIMVASTATIN CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SIMVASTATIN CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SIMVASTATIN IDH1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SIMVASTATIN NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17928392

Sources:
NCI
SIMVASTATIN AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: SIMVASTATIN
- Version: 01-August-2011
Alternate Names:

SIMVASTATIN Primary Drug Name

Drug Info:

Year of Approval 1991

Drug Class anticholesteremic agents

Publications:
TdgClinicalTrial: SIMVASTATIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antihypertensive agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: SIMVASTATIN

Version: 14-September-2017

Alternate Names:

C29454 NCI drug code

Drug Info:

Publications:

Han et al., 2005, HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo., Circulation

Hsieh et al., 2008, Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation., Toxicol. Sci.

Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.

DTC: SIMVASTATIN

Version: 02-September-2020

Alternate Names:

CHEMBL1064 ChEMBL Drug ID

Drug Info:

Publications:

MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: simvastatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics

de Keyser CE et al., 2013, Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study., Pharmacogenomics

Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther

TTD: Simvastatin
- Version: 2020.06.01
Alternate Names:

D0H0ND TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1064
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1064
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	HL 007, simvastatin + amlodipine
Novel drug target	Established target
Trial Name	MK-0542B, extended release niacin + laropiprant +simvastatin

SIMVASTATIN Drug Record

SIMVASTATIN chembl:CHEMBL1064 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19027114

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name HL 007, simvastatin + amlodipine Novel drug target Established target Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

PMIDs: 16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575

Sources: DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11566255

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16158080

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18854995 14625131

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30304062 21458191

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27839692 25753936

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19904013 18430057 16238680

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15936011

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23166513

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16955753

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19530961

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18663903

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20031551

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10720627

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10543307

Interaction Types & Directionality:

n/a

PMIDs:
19027114

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HL 007, simvastatin + amlodipine

Novel drug target Established target

Trial Name MK-0542B, extended release niacin + laropiprant +simvastatin

PMIDs:
16680159 18815589 18332269 18261733 17563401 16103896 15199031 12677170 12433810 12671581 11752352 12852453 12518039 16128575

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
11566255

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16158080

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18854995 14625131

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30304062 21458191

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27839692 25753936

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19904013 18430057 16238680

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15936011

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23166513

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16955753

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19530961

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18663903

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
20031551

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16103896

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10720627

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10543307

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17931083 15856070

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15781755

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16797728

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17600820

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18203812

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10736278

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25493567

Sources:
PharmGKB

Interaction Types & Directionality:

n/a